JUVE Patent

About Dr. Arwed Burrichter

Dr. Arwed Burrichter is a patent attorney and partner at COHAUSZ & FLORACK, advising leading international companies in the chemistry and life sciences sector. He holds a doctorate in chemistry and provides counselling on patents and licenses, particularly in the fields of chemistry & life sciences, pharmaceutical chemistry, polymer chemistry and biochemistry, and advises clients on the development of their intellectual property portfolios. Arwed Burrichter has extensive expertise and years of experience in infringement litigation, design protection and trademark portfolio management.

After studying chemistry in Bonn and Los Angeles, Arwed Burrichter received his doctorate in hydrocarbon chemistry from the University of Southern California in Los Angeles in 1997 under Nobel Laureate George A. Olah. After completing his training as a patent attorney, he worked for a renowned New York patent law firm. He has been admitted as a German Patent Attorney since 2000 and as a representative before the European Patent Office since 2002.

Arwed Burrichter speaks German, English and French.

Publications

• Second medical use claims in pharmaceutical patents – sharp sword or toothless tiger?
  https://www.cohausz-florack.de/en/more/blog/article/second-medical-use-claims-in-pharmaceutical-patents-sharp-sword-or-toothless-tiger/
• Deadly pitfalls and lessons learned – claiming priority at the EPO
  https://www.cohausz-florack.de/en/more/blog/article/deadly-pitfalls-and-lessons-learned-claiming-priority-at-the-epo/
• The need-to-know facts about patent term extensions in Europe
  https://www.cohausz-florack.de/en/more/blog/article/the-need-to-know-facts-about-patent-term-extensions-in-europe/
• Sprycel – new plausibility threshold for life sciences patents?
  https://www.cohausz-florack.de/en/more/blog/article/sprycel-new-plausibility-threshold-for-life-sciences-patents/
• Clinical trial disclosures – an obstacle to patentability in Europe
  https://www.cohausz-florack.de/en/more/blog/article/clinical-trial-disclosures-an-obstacle-to-patentability-in-europe/